Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-05-27 4:34 pm Sale | 2022-05-25 | 13D | Genocea Biosciences, Inc. GNCA | New Enterprise Associates 16, L.P. | 0 0.000% | -15,414,495 (Position Closed) | Filing History |
| 2022-02-14 4:09 pm Purchase | 2021-12-31 | 13G | Genocea Biosciences, Inc. GNCA | Commodore Capital LP | 3,079,756 5.400% | 208,132 (+7.25%) | Filing History |
| 2022-02-14 06:19 am Sale | 2021-12-31 | 13G | Genocea Biosciences, Inc. GNCA | Citadel Advisors LLC | 3,535,358 6.200% | -51,718 (-1.44%) | Filing History |
| 2022-02-11 7:54 pm Purchase | 2021-12-31 | 13G | Genocea Biosciences, Inc. GNCA | BIOTECHNOLOGY VALUE FUND L P | 5,930,353 9.990% | 644,804 (+12.20%) | Filing History |
| 2022-02-10 4:55 pm Purchase | 2021-12-31 | 13G | Genocea Biosciences, Inc. GNCA | GSK plc | 5,861,389 9.900% | 644,000 (+12.34%) | Filing History |
| 2021-04-13 7:08 pm Sale | 2020-07-24 | 13D | Genocea Biosciences, Inc. GNCA | New Enterprise Associates 16, L.P. | 15,414,495 26.300% | -1,558,333 (-9.18%) | Filing History |
| 2021-03-31 07:14 am Purchase | 2021-03-22 | 13G | Genocea Biosciences, Inc. GNCA | Commodore Capital LP | 2,871,624 5.400% | 2,871,624 (New Position) | Filing History |
| 2021-02-16 4:30 pm Purchase | 2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA | Citadel Advisors LLC | 3,587,076 6.700% | 154,690 (+4.51%) | Filing History |
| 2021-02-16 09:57 am Sale | 2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA | OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,769,170 3.300% | -290 (-0.02%) | Filing History |
| 2021-02-12 5:12 pm Purchase | 2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA | GSK plc | 5,217,389 9.900% | 1,540,622 (+41.90%) | Filing History |
| 2021-02-12 5:03 pm Purchase | 2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA | BIOTECHNOLOGY VALUE FUND L P | 5,285,549 9.990% | 2,123,881 (+67.18%) | Filing History |
| 2021-02-12 4:30 pm Sale | 2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA | Vivo Opportunity LLC | 613,437 1.200% | -830,401 (-57.51%) | Filing History |
| 2021-02-12 08:04 am Purchase | 2020-12-31 | 13G | Genocea Biosciences, Inc. GNCA | Avoro Capital Advisors LLC | 33,613,444 9.990% | 33,613,444 (New Position) | Filing History |